Zacks Research Analysts Lower Earnings Estimates for ACAD

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Zacks Research lowered their Q2 2025 earnings estimates for shares of ACADIA Pharmaceuticals in a report issued on Wednesday, May 28th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will earn $0.14 per share for the quarter, down from their prior forecast of $0.19. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share. Zacks Research also issued estimates for ACADIA Pharmaceuticals' Q3 2025 earnings at $0.14 EPS, Q4 2025 earnings at $0.13 EPS, Q2 2026 earnings at $0.19 EPS and Q1 2027 earnings at $0.24 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.01. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The firm had revenue of $244.32 million during the quarter, compared to analyst estimates of $239.32 million. During the same quarter in the previous year, the business earned $0.10 EPS. The business's quarterly revenue was up 18.7% compared to the same quarter last year.

Several other research firms have also recently weighed in on ACAD. Oppenheimer reiterated a "market perform" rating on shares of ACADIA Pharmaceuticals in a report on Friday, May 16th. HC Wainwright upped their price target on shares of ACADIA Pharmaceuticals from $27.00 to $32.00 and gave the company a "buy" rating in a report on Monday, May 19th. Deutsche Bank Aktiengesellschaft upgraded shares of ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating and raised their price objective for the stock from $20.00 to $35.00 in a report on Wednesday, May 21st. Mizuho upped their target price on shares of ACADIA Pharmaceuticals from $20.00 to $23.00 and gave the stock a "neutral" rating in a research note on Monday, May 19th. Finally, Robert W. Baird increased their target price on ACADIA Pharmaceuticals from $28.00 to $31.00 and gave the stock an "outperform" rating in a report on Monday, May 19th. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $26.83.

ACADIA Pharmaceuticals Stock Performance

NASDAQ:ACAD traded down $0.26 during trading hours on Thursday, hitting $21.32. The stock had a trading volume of 563,182 shares, compared to its average volume of 1,933,755. The business's 50 day moving average is $16.87 and its 200-day moving average is $17.48. The company has a market cap of $3.57 billion, a price-to-earnings ratio of 27.33 and a beta of 0.47. ACADIA Pharmaceuticals has a one year low of $13.40 and a one year high of $25.23.

Insider Activity at ACADIA Pharmaceuticals

In related news, Director Elizabeth A. Garofalo sold 4,919 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total transaction of $89,673.37. Following the sale, the director now owns 17,595 shares of the company's stock, valued at approximately $320,756.85. This represents a 21.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Mark C. Schneyer sold 3,171 shares of ACADIA Pharmaceuticals stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $17.05, for a total value of $54,065.55. Following the sale, the executive vice president now owns 56,889 shares of the company's stock, valued at approximately $969,957.45. This trade represents a 5.28% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 23,746 shares of company stock valued at $428,221. 26.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ACAD. Vanguard Group Inc. increased its holdings in ACADIA Pharmaceuticals by 9.0% during the 1st quarter. Vanguard Group Inc. now owns 15,203,234 shares of the biopharmaceutical company's stock valued at $252,526,000 after purchasing an additional 1,255,594 shares during the period. Assenagon Asset Management S.A. purchased a new position in shares of ACADIA Pharmaceuticals during the first quarter valued at approximately $60,845,000. Fred Alger Management LLC raised its holdings in shares of ACADIA Pharmaceuticals by 2.0% during the first quarter. Fred Alger Management LLC now owns 2,769,828 shares of the biopharmaceutical company's stock valued at $46,007,000 after acquiring an additional 54,899 shares in the last quarter. First Trust Advisors LP raised its holdings in shares of ACADIA Pharmaceuticals by 27.0% during the fourth quarter. First Trust Advisors LP now owns 2,700,125 shares of the biopharmaceutical company's stock valued at $49,547,000 after acquiring an additional 574,251 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in ACADIA Pharmaceuticals in the fourth quarter worth $40,935,000. 96.71% of the stock is owned by institutional investors.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.